中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (7): 501-506.doi: 10.3969/j.issn.1007-3969.2014.07.004

• 论著 • 上一篇    下一篇

GATA5甲基化在结直肠癌血浆和粪便中的检测及临床诊断价值

张学松1,张谢1,黄诗良1,陆宏娜1,王丹萍2,黄志刚1   

  1. 1.浙江省宁波市医疗中心李惠利医院消化内科,浙江 宁波 315040;
    2.宁波大学医学院,浙江 宁波315211
  • 出版日期:2014-07-30 发布日期:2014-07-29
  • 通信作者: 黄志刚 E-mail:Huangzg@foxmail.com
  • 基金资助:
    宁波市社会发展基金项目(No:2011C50022);宁波市科技创新团队(No: 2013B82010)

Detection of GATA5 gene methylation in plasma and stool of colorectal cancer and the clinical diagnosis

ZHANG Xue-song1,ZHANG Xie1,HUANG Shi-liang1,LU Hong-na1,Wang Dan-ping2,Huang Zhi-gang1   

  1. 1.Department of Gastroenterology, Ningbo Medical Treatment Center Li Huili Hospital, Ningbo Zhejiang 315040, China;
    2.School of Medicine, Ningbo University, Ningbo Zhejiang 315211, China
  • Published:2014-07-30 Online:2014-07-29
  • Contact: Huang Zhi-gang E-mail: Huangzg@foxmail.com

摘要:

背景与目的:结直肠癌(colorectal cancerCRC)是全球发病率第三,死亡率第四的恶性肿瘤。遗传学及表观遗传学的改变引发抑癌基因甲基化表达沉默是CRC发生的重要原因,本研究旨在探讨血浆、粪便GATA5启动子甲基化检测在CRC临床诊断中的应用价值。方法:收集34例健康体检者和43CRC患者的血浆和配对的粪便标本。采用甲基化特异性PCR(methylation specific PCR methodMSP)检测其血浆、粪便中GATA5甲基化水平,并分析其与临床病理特征相关性。结果:MSP结果显示CRC患者血浆、粪便中GATA5启动子甲基化率(60.74%76.60%)高于健康者发生率(26.47%32.35%),差异均有统计学意义(P值分别为0.006 70.000 2)CRC患者血浆甲基化发生率与临床分期(P=0.000 5)、淋巴结转移(P=0.020)密切相关,而粪便GATA5甲基化水平与临床病理特征无统计学意义。结论:检测粪便GATA5甲基化水平并辅以血浆GATA5甲基化水平可作为一种简单、非侵入、敏感及特异的方法应用于CRC患者的临床诊断。

关键词: GATA5, 结直肠癌, 甲基化特异性PCR, 甲基化

Abstract:

Background and purpose: Colorectal cancer (CRC) is a malignancy which is the third incidence and the fourth mortality in the worldwide. The main reason for the development of CRC is that the changes of genetic and epigenetic causes the tumor suppressor gene methylation silencing. This study aimed to investigate the plasma and stool GATA5 gene promoter methylation was detected in clinical diagnosis of CRC. Methods: To collect the paired plasma and stool specimens of 34 cases of healthy and 43 cases of patients with CRC. Methylation specific PCR (MSP) was respectively detected the GATA5 gene methylation levels of GATA5 gene in plasma and stool. And then separately analyzed their correlations with clinical and pathological parameters in gastric carcinoma. Results: The result of MSP showed that GATA5 gene promoter methylation rates in plasma and stool of CRC patients were 60.74%, 76.60%, respectively, were higher than those of healthy persons (6.47%, 32.35%). And the differences were statistically significant (P=0.006 7, P=0.000 2, respectively). GATA5 gene methylation rates in plasma of CRC patients were closely related to clinical stage (P=0.000 5) and lymph node metastasis(P=0.020), while GATA5 gene methylation rates in stool of CRC patients had no significant with clinical and pathological parameters. Conclusion: Detection of faecal GATA5 gene methylation level and supplemented plasma GATA5 gene methylation level can become a simple, non-invasive, sensitive and specific method for clinical diagnosis of CRC.

Key words: GATA5 gene, Colorectal cancer, Methylation specific PCR, Methylation